{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:58:21Z","timestamp":1789941501448,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>Potentially inappropriate medication (PIM) use is prevalent in older adults and is associated with adverse events, hospitalisation and mortality. We assessed the patterns and associations of PIM use in older adults with mild-to-moderate Alzheimer\u2019s Disease (AD), who may represent a particularly vulnerable group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Analysis of data from NILVad, an 18-month Randomised Control Trial of Nilvadapine in mild-to-moderate AD. The v2 STOPP criteria were applied in duplicate to identify PIM use. Associations between PIM use and adverse events\/unscheduled healthcare visits in addition to the associations between PIM use and AD progression were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting and Participants<\/jats:title>\n                  <jats:p>448 older adults with mild-to-moderate AD from 23 centres in nine European countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 448 participants (mean age: 72.56\u2009\u00b1\u20098.19\u00a0years), over half (55.8%) were prescribed a PIM with 30.1% being prescribed 2+ PIMs. The most frequent PIMs were (i) long-term benzodiazepines (11.6% N\u2009=\u200952\/448), (ii) selective serotonin reuptake inhibitors without appropriate indication (11.1% N\u2009=\u200950\/448), and (iii) Proton-Pump Inhibitors (PPIs) without appropriate indication (10.7% N\u2009=\u200948\/448). Increasing number of PIMs was associated with a greater risk of adverse events (IRR 1.17, 1.13\u20131.19, P\u2009&amp;lt;\u20090.001), serious adverse events (IRR 1.27; 1.17\u20131.37, P\u2009&amp;lt;\u20090.001), unscheduled hospitalisations (IRR 1.16, 1.03\u20131.30, P\u2009=\u20090.016) and GP visits (IRR 1.22, 1.15\u20131.28, P\u2009&amp;lt;\u20090.001). PIM use was not associated with dementia progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions and Implications<\/jats:title>\n                  <jats:p>PIM use is highly prevalent in mild-to-moderate AD and is associated with adverse events and unscheduled healthcare utilisation. Further attention to de-prescribing in this vulnerable group is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ageing\/afaa067","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T20:09:50Z","timestamp":1585166990000},"page":"580-587","source":"Crossref","is-referenced-by-count":16,"title":["Potentially inappropriate medication use in older adults with mild-moderate Alzheimer\u2019s disease: prevalence and associations with adverse events"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-8236","authenticated-orcid":false,"given":"Claire","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Age-Related Healthcare, Tallaght University Hospital, Dublin, Ireland"},{"name":"Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-510X","authenticated-orcid":false,"given":"Adam H","family":"Dyer","sequence":"first","affiliation":[{"name":"Department of Age-Related Healthcare, Tallaght University Hospital, Dublin, Ireland"},{"name":"Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lawlor","sequence":"first","affiliation":[{"name":"Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland"},{"name":"Mercer\u2019s Institute for Research on Ageing, St James\u2019s Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P","family":"Kennelly","sequence":"first","affiliation":[{"name":"Department of Age-Related Healthcare, Tallaght University Hospital, Dublin, Ireland"},{"name":"Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NILVAD Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"2020070207442818300_ref1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2","volume":"44","author":"O\u2019Mahony","year":"2015","journal-title":"Age Ageing"},{"key":"2020070207442818300_ref2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(07)61091-5","article-title":"Appropriate prescribing in elderly people how well can it measured and optimised","volume":"370","author":"Spinewine","year":"2007","journal-title":"Lancet"},{"key":"2020070207442818300_ref3","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/gps.5160","article-title":"Potentially inappropriate prescribing in people with dementia: an Australian population-based study","volume":"34","author":"Eshetie","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"2020070207442818300_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-019-01239-x","article-title":"The relationship between common geriatric syndromes and potentially inappropriate medication use among older adults. Ageing clinical and experimental research. 2019","author":"Kucukdagli","journal-title":"E pub ahead of print"},{"key":"2020070207442818300_ref5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1089\/jpm.2018.0070","article-title":"Potentially inappropriate prescribing in Australian nursing home residents with advanced dementia; a substudy of the IDEAL study","volume":"10","author":"Disalvo","year":"2018","journal-title":"J Palliat Med"},{"key":"2020070207442818300_ref6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00228-018-02612-x","article-title":"Identifying potentially inappropriate prescribing in older people with dementia: a systematic review","volume":"75","author":"Hukins","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2020070207442818300_ref7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3233\/JAD-151177","article-title":"Potentially inappropriate prescribing amoung people with dementia in primary care: a retrospective cross sectional study using the enhanced prescribing database","volume":"52","author":"Barry","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2020070207442818300_ref8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/13814788.2017.1288211","article-title":"Prevalence of inappropriate medication use in residential long term care facilities for the elderly - a systematic review","volume":"1","author":"Storms","year":"2017","journal-title":"Eur J Gen Pract"},{"key":"2020070207442818300_ref9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40266-015-0287-4","volume":"32","author":"Sk\u00f6ldunger","year":"2015","journal-title":"Drugs Aging"},{"key":"2020070207442818300_ref10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40266-017-0513-3","article-title":"Associations between the drug burden index. Potentially inappropriate medications and quality of life in residential aged care","volume":"35","author":"Harrison","year":"2018","journal-title":"Drugs Aging"},{"key":"2020070207442818300_ref11","doi-asserted-by":"publisher","first-page":"e026171","DOI":"10.1136\/bmjopen-2018-026171","article-title":"How do potentially inappropriate medications and polypharmacy affect mortality in frail and non frail cognitively impaired older adults? A cohort study","volume":"14","author":"Porter","year":"2019","journal-title":"BMJ Open"},{"key":"2020070207442818300_ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019853069","article-title":"Associations between potentially inappropriate medications and adverse health outcomes in the elderly; a systematic review and meta analysis","volume":"25","author":"Xing","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2020070207442818300_ref13","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/Gerona\/gly078","article-title":"The impact of dementia diagnosis on patterns of potentially inappropriate medication use among older adults. Journal gerontology","volume":"73","author":"Gnjidic","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2020070207442818300_ref14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ageing\/afx147","article-title":"Potentially inappropriate medication among people with dementia in eight European countries","volume":"47","author":"Anna","year":"2018","journal-title":"Age Ageing"},{"key":"2020070207442818300_ref15","doi-asserted-by":"publisher","first-page":"e00634","DOI":"10.1136\/bmjopen-2014-006364","article-title":"NILVAD protocol a European multicentre double blind placebo controlled trial of Nilvadipine in mild to moderate Alzheimer\u2019s disease","volume":"4","author":"Lawlor","year":"2014","journal-title":"BMJ Open"},{"key":"2020070207442818300_ref16","doi-asserted-by":"publisher","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer\u2019s disease a randomised controlled trial","volume":"15","author":"Lawlor","journal-title":"PLoS Med"},{"key":"2020070207442818300_ref17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/archinternmmed.2011.215","article-title":"Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients","volume":"171","author":"Hamilton","year":"2011","journal-title":"Arch Intern Med"},{"key":"2020070207442818300_ref18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"2020070207442818300_ref19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and the risk of Alzheimer\u2019s disease: case control study","volume":"348","author":"Billioti De Gage","year":"2014","journal-title":"BMJ"},{"key":"2020070207442818300_ref20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jamda.2019.08.006","article-title":"Cognitive consequences of long-term benzodiazepine and related drug use in people living with mild to moderate Alzheimer disease: data from NILVAD","volume":"21","author":"Dyer","year":"2020","journal-title":"JAMDA"},{"key":"2020070207442818300_ref21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-014-1684-z","article-title":"Risk of hip fracture amoung older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study","volume":"70","author":"Bakken","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2020070207442818300_ref22","article-title":"Guidance of the use of zaleplon, zolpidem and zopiclone for the short term management of insomnia","author":"The National Institute for Health And Care Excellence (NICE) 2004"},{"key":"2020070207442818300_ref23","first-page":"2227","article-title":"Beers criteria update expert panel. American Geriatrics Society","volume":"63","author":"American Geriatrics Society (2015)","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"2020070207442818300_ref24","author":"The national institute for health and care excellence (NICE) 2014"},{"key":"2020070207442818300_ref25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1176\/appi.ajp2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease; phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"Am J Psychiatr"},{"key":"2020070207442818300_ref26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12553-012-0037-0","article-title":"E-prescription across Europe","volume":"3","author":"Kierkegaard","year":"2013","journal-title":"Health Technol"},{"key":"2020070207442818300_ref27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/qjmed\/hcw114","article-title":"Dementia in the acute hospital: the prevalence and clinical outcomes of acutely unwell patients with dementia","volume":"110","author":"Briggs","year":"2017","journal-title":"QJM"},{"key":"2020070207442818300_ref28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/Gerona\/glw140","article-title":"Impact of potentially inappropriate prescribing on adverse drug events health related quality of life and emergency hospital attendance in older people attending general practice. A prospective cohort study","volume":"71","author":"Wallace","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2020070207442818300_ref29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-015-0378-5","article-title":"Appropriate Polypharmacy and medicine safety: when many is not too many","volume":"39","author":"Cadogan","year":"2016","journal-title":"Drug Saf"},{"key":"2020070207442818300_ref30","first-page":"72","article-title":"D O\u2019Mahony STOPP (screening tool of older persons prescriptions) and START (screening tool to alert doctors to right treatment)consensus validation","volume":"46","author":"Gallagher","year":"2008","journal-title":"Format: AbstractSend to Int J Clin Pharmacol Ther"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ageing\/article-pdf\/49\/4\/580\/33456184\/afaa067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ageing\/article-pdf\/49\/4\/580\/33456184\/afaa067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:46:43Z","timestamp":1593690403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/49\/4\/580\/5848663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,30]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afaa067","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,5,30]]}}}